Automation and Compound Management (ACOMM)

National Center For Advancing Translational Sciences

Investigators

Linked publications, trials & patents

Abstract

The Automation and Compound Management (ACOMM) staffs provide support to the NCATS activities in high-throughput screening, assay development, and optimization as well as follow-up and dose-response library-plating services for NCATS screening activities. The compound management team works in conjunction with the automation team to provide follow-up and dose-response library-plating services for NCATS screening activities. Systems supported by the automation team include primary screening system, secondary screening system, Tox21 screening system, RNAi screening system, and two new systems starting this year: the RNAi hit picking system for assay follow ups and the High Resolution Biosystems (HRB) acoustic plating system. These two new systems have greatly expanded the capabilities of a variety of biology groups at NCATS; the HRB system allows us to generate assay-ready plates for screening in a capacity that we were never able to achieve prior. The primary screening system utilizes three robotic arms for plate transportation, a storage capacity of more than 3 million compound wells (approximately 2,000 1,536-well compound plates), and more than 1.5 million assay wells (approximately 1,100 1,536-well assay plates) to achieve a world-class screening productivity while maintaining the high level of data quality required by researchers. It also has the ability to run multiple assays in parallel. Center experts have developed custom software to monitor and control the system, in addition to archiving the complete process history for every screen in real time. The secondary screening system uses two robotic arms for plate transportation and a storage capacity of nearly 1 million compound or assay wells (about 600 1,536-well compound or assay plates) to screen smaller scale compound libraries not present on the primary screening system. This platform is designed to complement the primary system, and it is easily customizable, allowing for the rapid integration of additional screening technologies. The ACOMM team additionally provides screening system services to intramural programs within NCATS. The Tox21 screening system contains a single robotic arm for plate transportation and a storage capacity of about 1.5 million compound wells (about 1,000 1,536-well compound plates) and more than 1.5 million assay wells (approximately 1,100 1,536-well assay plates). With a pin tool and two acoustic dispensers for compound addition, four low-volume dispensers for reagent addition, and three plate readers enabling a variety of assay detection methods, this system can rapidly screen, in triplicate, the Toxicology in the 21st Century (Tox21) library of 10,000 compounds. NCATS experts monitor and control this system with the same custom software used for the primary screening system. The RNAi screening system has two robotic arms for plate transportation with incubators for assay plate storage and plate stackers to facilitate continuous system operation. A multichannel pipettor, low volume dispensers, an aspirator for plate washing and two different plate readers support a wide variety of detection methods for this RNAi-focused system. This year has also seen a tremendous increase in the work done for the newly formed Stem Cell Translation Laboratory. Various team members have provided a large amount of support with a vast array of equipment including automated tissue culture systems, flow cytometers, cell sorters and high content imagers. All of these resources require a tremendous amount of expertise to operate and maintain. In the past year, the ACOMM group has begun to act as a core facility for these technologies, enabling different biology groups to increase their capabilities. Related to the high content imagers, more high content assays were run in the past year due to the increased capabilities as compared to the previous four years combined. Finally, the ACOMM group was able to act as the incubator for the nascent NCATS Tissue Printing group. In 2015, the group established official funding through the Cures Acceleration Network (CAN) and is now more formally funded. We have two active areas of engagement: the creation of a skin model and the collaboration with NEI for the creation of a retina model. Both of these efforts have seen great progress made in the last year; and with the onset of official funding, a large amount of equipment has been ordered to increase the groups capabilities.